

# Mesothelioma Essential Update 2022

Joint Event by Mesothelioma UK and BTOG



Thursday 1st December 2022  
Cavendish Conference Centre, London



Applied for CPD credits from the  
Federation of the Royal Colleges  
of Physicians of the United  
Kingdom (Ref: 142511)

## 08:45 Registration and Refreshments

09:10 Open – Welcome

Chairs: Riyaz Shah and Leah Taylor

### Equity and Excellence in the NHS

09:15 National Mesothelioma Audit Now & Planning Ahead

Michael Peake

09:30 Scottish Mesothelioma Network

Kevin Blyth

09:45 National Peritoneal Service

Faheez Mohamed

10:00 Panel

### The Genetics and Pathology of Mesothelioma

Chair: Andrew Nicholson

10:20 Role of Genetics in Mesothelioma

Marion McFarlane

10:40 Pathology in practice and current challenges

Cathy Richards

11:00 Panel

## 11:15 Refreshments and Exhibition

### What are the Standard Treatment Options for Pleural Mesothelioma in the UK?

Chair & Moderator: Riyaz Shah

11:45 The future of mesothelioma surgery in the UK after MARS2?

Eric Lim

12:00 1<sup>st</sup> line SACT for pleural mesothelioma

Sanjay Popat

12:15 SACT options after 1<sup>st</sup> line

Peter Szlosarek

12:30 Case Studies and Debate

## 13:00 Lunch and Exhibition

### Supporting Patients

Chair: Liz Darlison

13:45 How does Mesothelioma UK support patients?

Leah Taylor

14:00 What is the Legal Process? A Start to Finish Guide

Bridget Collier

14:15 Supporting Patients to get the Right Benefits

Sarah Thomas

14:30 Panel

## 14:45 Refreshments and Exhibition

### Radiotherapy and Pleural Session

Chair: Nick Maskell

15:15 Radiotherapy in Current-day Practice

Neil Bayman

15:30 The Future of Radiotherapy

Crispin Hiley

15:45 Establishing an ideal pleural service

Christopher Craig

16:00 Nurse-led IPC service

Jenn Latham

16:15 Panel

16:30 Closing Remarks and Final Q&A

Riyaz Shah and Leah Taylor

## 16:40 BTOG/Mesothelioma UK Informal Networking Reception

Please note that except for the sponsor of the Informal Networking Reception – sponsors are not associated with, nor have they contributed in any way to this reception.

17:40 Close

## **Biographies**

**Dr Neil Bayman** graduated from the University of Manchester and trained as a Clinical Oncologist in Manchester. His primary speciality is lung cancer with a particular interest in combined treatment therapy and the development of advanced radiotherapy, including SABR for treating lung cancers. He is highly committed to research and is a core collaborator on combined modality therapy trials in non-small cell lung cancer and small cell lung cancer, and lung cancer radiotherapy trials. He leads on the recently funded PIT trial, a phase III study aiming to establish the role of prophylactic irradiation of portal tracts in patients with malignant pleural mesothelioma. Dr Bayman is Clinical Director of the Manchester Cancer Lung Pathway, leading the Lung Cancer Pathway Board to implement changes aiming to improve clinical outcomes and patient experience for lung cancer patients in Greater Manchester. He represents Greater Manchester on the NHS England Lung Cancer Clinical Reference Group.

**Professor Kevin Blyth** is a Consultant Respiratory Physician and Clinical Academic based at the Queen Elizabeth University Hospital and the Institute of Cancer Sciences/Beatson Institute at the University of Glasgow. He leads the Glasgow Pleural Disease Unit, which delivers diagnostic and therapeutic services, including thoracoscopy, and a range of clinical trials. He founded and is Director of the Macmillan Scottish Mesothelioma Network, which coordinates clinical care and access to trials for all patients in Scotland. He is an NHS Scotland Research (NRS) Senior Research Fellow and leads a translational research program focused on pleural disease and thoracic malignancy and has a particular interest in Mesothelioma. He is Principal Investigator of the CRUK PREDICT-Meso International Accelerator Network.

**Bridget Collier** is a partner with Fieldfisher LLP and an accredited Mesothelioma specialist lawyer with the Association of Personal Injury Lawyers (APIL). Her case load comprises of claims for those with asbestos related diseases. She has also sat on the Diffuse Mesothelioma Payment Scheme Oversight Committee and APIL's Executive Committee.

**Christopher Craig** is Respiratory Physician at Manchester University NHS Foundation Trust. Dr Craig completed his undergraduate training in the university of Glasgow in 2011 after which he stayed in Glasgow for early post graduate training and then moved to the north-west of England for specialty training. He achieved a CCT in respiratory and general medicine, and then completed a post CCT fellowship in lung cancer and pleural medicine. Dr Craig is interested in interventional procedures including medical thoracoscopy, chest drains, endobronchial US and navigational bronchoscopy. He was appointed as a substantive consultant in August 2021. Dr Craig has completed a PG cert in post graduate medical education and has a keen interest in undergraduate and postgraduate supervision and teaching.

**Liz Darlison MBE** has enjoyed over 38 years of clinical practice at the University Hospitals of Leicester, 22 of them in thoracic oncology. Currently she is a Consultant Nurse at UHL and is also CEO of Mesothelioma UK, the national charity for Mesothelioma. Liz's interests within thoracic oncology have always focused on developing the nursing contribution, within the multidisciplinary team, to improve outcomes but also the patient and carer experience across the whole cancer pathway.

**Dr Crispin Hiley** is an Associate Professor with tenure in Radiation Oncology at UCL and an Honorary Consultant Clinical Oncologist at UCLH. He graduated with honours from the University in Manchester in 2005. He has trained in Oncology at many centres of excellence both in the UK and abroad. These include the Christie Hospital, the MD Anderson Cancer Centre (Houston, USA), Kings College (NIHR Clinical Lecturer) and the Royal Marsden (NIHR Clinical Fellow). He completed a PhD at the University of London with the Barts Cancer Institute and a postdoctoral research Fellowship the Francis Crick Institute and the UCL Cancer institute. He became a consultant in 2018 joining the thoracic oncology team at UCLH. In addition, he is the UCLH Lead for Lung Proton Therapy, Deputy Lead of Clinical Trials Theme for the CRUK Lung Cancer Centre of Excellence and NIHR Clinical Research Network Speciality Research Lead Radiotherapy for North London. He heads a research group at the UCL Cancer Institute focused on understanding resistance to radiation therapy. Dr Hiley specialises in non-surgical treatments for all types of lung cancer. He has expertise in chemotherapy, immunotherapy and radiotherapy including state of the art radiotherapy techniques including Volumetric Arc Therapy (VMAT), Intensity Modulated Radiotherapy (IMRT), Image Guided Radiotherapy (IGRT), Proton Therapy and Stereotactic Radiotherapy (SBRT). Dr Hiley has expertise in

treating all sites of metastatic disease (except for brain) with stereotactic radiotherapy including lung, liver, lymph nodes, adrenal glands, spine and other bone sites. He is the principal investigator and national chief investigator for several academic and commercial clinical trials in lung cancer. He has published in several of the world's leading journals including NEJM, The Lancet, Nature and Cell. He is a member of the expert group which authored the Radiotherapy for Lung Cancer Royal College of Radiologists Consensus Statement.

**Jenn Latham** has been an Advanced Lung Cancer Nurse, specialising in early detection, respiratory medicine and pleural effusions. Throughout her career, Jenn previously worked as a staff nurse in acute medicine, ITU, Emergency Department and was a ward-based nurse practitioner, mainly in respiratory, for six years. Jenn has focused on pleural diseases and pleural metastases including lung, breast and bowel cancers. She is also a national representative on the British Thoracic Society Pleural Sub Advisory Group.

**Eric Lim** is Consultant thoracic surgeon at Royal Brompton Hospital and Professor of thoracic surgery at Imperial College London. He graduated from the University of Sheffield and trained in cardiothoracic surgery in Cambridge and London. He was the recipient of an MRC scholarship and awarded MSc in Biostatistics and MD for surgical research. Professor Lim specialises in thoracic surgical diseases, with a strong focus on patient care, aspiring to make thoracic surgery that causes the least amount of pain and disruption to the patient's life. He led multiple NIHR funded multi-centre randomised surgical trials including VIOLET, MARS 2 and RAMON and authored numerous international guidelines on thoracic surgery and oncology.

**Nick Maskell** is a Professor of Respiratory Medicine at University of Bristol (UoB) and Honorary Consultant Chest Physician at North Bristol NHS Trust. He was appointed as a consultant there in 2004. He leads the pleural service at Southmead hospital and is the head of the Academic Respiratory Unit at UoB. He has a major interest in mesothelioma, running a tertiary mesothelioma clinic and chairing the weekly regional mesothelioma MDT. He chaired the current BTS mesothelioma guideline group and was on the committee for the ERS mesothelioma guidelines. He is also a co-chair of the forthcoming BTS pleural disease guidelines (2021) and is an advisor to the NPSA on pleural safety matters related to pleural interventions. He has been the senior author in large published randomised controlled trials in mesothelioma that have led to changes in practice. He also is a co-founder of the Avon Mesothelioma Foundation (AMF), a local charity supporting mesothelioma research and patient care.

**Marion McFarlane** is Deputy Director and MRC Investigator at MRC Toxicology Unit, University of Cambridge.

**Faheez Mohamed** graduated from the University of Edinburgh and underwent surgical training in the Northeast of England. He was awarded a Doctor of Medicine in 2005 from the University of Newcastle based on research into intraperitoneal chemotherapy performed at the Washington Cancer Institute, USA under the supervision of Dr Paul Sugarbaker. He was appointed Consultant Surgeon at the Peritoneal Malignancy Institute, Basingstoke in 2009 with an interest in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the treatment of peritoneal malignancy. Mr Mohamed is a specialist advisor to NICE for Peritoneal Malignancy and is the Clinical Lead for the UK Colorectal Peritoneal Metastases Clinical Database. He is actively involved in clinical and basic science research in the field of peritoneal malignancy and has served on the Research and Audit Committee of the Association of Coloproctology of Great Britain and Ireland. He is Vice Chair of the EuroPMP international research consortium and Medical Advisor to Pseudomyxoma Survivor, a charity set up to support patients with Pseudomyxoma Peritonei.

He is on the Advisory Board of The Mavis Nye Foundation for helping support victims of asbestos related cancer such as mesothelioma and is a member of the Clinical Expert Panel for Meso UK. He continues to teach and lecture nationally and internationally on colorectal cancer, pseudomyxoma peritonei, peritoneal mesothelioma and intraperitoneal chemotherapy. Mr Mohamed was Clinical Director of the Department of General Surgery and Urology at Hampshire Hospitals Foundation Trust from 2017 to 2021. His clinical interests include colonoscopy, laparoscopic surgery and treatment of advanced colorectal and other peritoneal cancers with Cytoreductive Surgery and HIPEC.

**Professor Andrew Nicholson** is a consultant histopathologist specialising in thoracic pathology, and an honorary professor of respiratory pathology at the National Heart and Lung Institute, Imperial College London. He has particular expertise in thoracic pathology (lung and mediastinum) and conducts research into lung cancer and

interstitial lung disease in particular. He reports between 200 and 300 referrals from clinicians and other pathologists, nationally and internationally, each year.

**Professor Michael Peake OBE** is Clinical Co-Director of the Centre for Cancer Outcomes, University College London Hospitals, Specialist Advisor to Cancer Research UK, Hon. Professor of Respiratory Medicine, University of Leicester and Hon. Clinical Lead in the National Cancer Registration and Analysis Service. He established the National Lung Cancer Audit and the UK Lung Cancer Coalition, co-founded Mesothelioma UK and the British Thoracic Oncology Group. He has been involved in national cancer policy since the 1990s and published widely, major interests being early cancer diagnosis and improving outcomes for patients by proper service configuration, supported by clinical outcome data. He was awarded an OBE in the Queen's Birthday Honors list in 2020 for his services to medicine.

**Professor Sanjay Popat** BSc MBBS FRCP PhD is a Consultant Medical Oncologist at The Royal Marsden, Professor of Thoracic Oncology at the Institute of Cancer Research and is an internationally recognized expert in the treatment of lung cancer, mesothelioma and cancers of the thymus (thymoma and thymic carcinoma). Professor Popat qualified in 1994 from Guy's and St Thomas' Hospitals with triple distinction and was awarded a PhD in Molecular Genetics in 2002, undertaking a postdoctoral Clinician Scientist Fellowship and a HEFCE Clinical Senior Lectureship thereafter. He has been awarded nationally and internationally competitive prizes for his research, in addition to four research fellowships. His research interests include the complexities of genetic profiling in cancer, as well as developing novel drug treatments through clinical trials. He also holds several national and international roles. Nationally, Professor Popat Chairs the British Thoracic Oncology Group (BTOG) Steering Committee, is Co-Director for the NIHR London South Clinical Research Network Cancer Division, the NIHR Lung Cancer National Specialty Lead and is past Sub-group Chair of the NCRI Lung Group. Internationally, he sits on the Foundation Council of the European Thoracic Oncology Platform (ETOP) and is active in the European Society of Medical Oncology (ESMO) where he has co-authored European Clinical Practice Guidelines for Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Mesothelioma. His research collaborations with industry have led to licensing of several drugs globally, leading to implementation in International treatment guidelines and NHS funding approvals. Professor Popat is often an invited Clinical Expert to the National Institute for Health and Care Excellence (NICE) and sits on several committees overseeing the safety and governance for ongoing UK and international clinical trials. Sanjay is a strong advocate for patient education and support and is clinical advisor to several patient-facing cancer charities.

**Cathy Richards** is a Consultant Histopathologist at the Leicester Royal Infirmary NHS Trust.

**Dr Riyaz Shah** qualified from Guy's and St Thomas Hospitals in 1994 and obtained Membership of the Royal College of Physicians of London in 1997. He completed junior medical training in London and was subsequently awarded an Imperial Cancer Research Fund Clinical Research Fellowship that led to the completion of a PhD from Imperial College/Hammersmith Hospital (1998-2001). His research focused on gene transcriptional irregularities in cancer and gene therapy. Dr Shah completed Medical Oncology training at The Royal Marsden Hospital (2002-2006) before being appointed as a Consultant Medical Oncologist at the Kent Oncology Centre (2006-). He was awarded an ASCO Foundation Merit Award in 2005 for his work in a cancer known as carcinosarcoma. Dr Shah specialises in thoracic and gastrointestinal malignancies and provides NHS clinics at Darent Valley, Maidstone and Tunbridge Wells Hospitals. He is active in several local and national committees. At the time of writing he is the Chairman of the Lung Tumour Site Specific Group for the Kent Cancer Collaborative, Lead for Research at KOC, Member of the NCRI Lung Clinical Studies Group and Member of the Thoracic Surgery Clinical Reference Group. He has a major interest in clinical research and acts as principal investigator on many trials in Kent. He was the UK Chief Investigator of the Lux LUNG 5 trial. He has published widely and is regularly invited to speak at local, national and international meetings.

**Peter Szlosarek** is Professor of Medical Oncology at Cancer Research UK Barts Centre. He graduated in 1994 from King's College, London with degrees in Pharmacology, Medicine and Surgery, receiving the Pharmacology and Therapeutics Intercalated BSc Prize and Legg Prize in Surgical Pathology. He obtained the MRCP in 1997, and subsequently trained in medical oncology at St. George's, Guy's and St. Bartholomew's Hospitals, completing a PhD on the molecular biology of TNF- $\alpha$  in ovarian cancer and a postdoctoral position in the Centre for Cancer and Inflammation under Prof Balkwill in 2005. After a substantive NHS oncology consultant post, he re-joined the BCI

as a Principal Investigator in 2008. My translational lab program focuses on aberrant tumour arginine metabolism and inflammation and is closely allied to my clinical interests in the treatment of mesothelial, lung and skin cancers.

**Sarah Thomas** has been a benefits specialist for over 10 years, previously working for Citizens Advice and Local Authority Housing. For the last three years she has specialised in supporting people with mesothelioma claim the benefits and government compensation they are entitled to. She works within the mesothelioma community in North East England to ensure patients have access to the full network of support providers

**Leah Taylor** is a Clinical Nurse Specialist at Northumbria NHS Foundation Trust. Leah Taylor is Head of Nursing for Mesothelioma UK. In this role, Leah works closely with the charity's operational team and trustees, and will provide strategic leadership of the charity's UK network of 34 Clinical Nurse Specialists. Leah stepped up from her previous position as a Mesothelioma UK Team Leader for the North of England, and is based at the Wansbeck General Hospital, part of Northumbria Healthcare NHS Foundation Trust.

**With Thanks to Sponsors of this Educational Meeting  
Sponsors have not been involved or influenced  
the content and the agenda of the meeting.**

**Premier Gold**



**Silver**



**Bronze**

